ARROWHEAD PHARMACEUTICALS IN ARWR
ASignal's systematic analysis rates ARWR as Neutral.
Reflects the latest available analysis · analyzed Jul 22, 2026
The case on ARWR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD histogram expansion indicating strengthening momentum
- Price trading above 20-day and 50-day moving averages (SMA20: 79.22, SMA50: 77.54)
- Strong liquidity position with current ratio of 6.23x and quick ratio of 6.09x
- High cash reserves ($1.78B) relative to debt ($1.38B), providing runway for development
- Negative operating cash flow (-$36.31M) and free cash flow (-$46.12M)
- Deteriorating revenue growth (YoY: -86.40%)
- High debt-to-equity ratio (2.31x) signaling elevated financial risk
- Negative profit, operating, and return on equity margins
- Extremely high valuation multiples: price-to-sales (20.53x), price-to-book (20.75x), and negative EV/EBITDA (-51.31x)
See the full verdict on ARWR
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ARWR
Most investors never get a second opinion, let alone several. ASignal runs ARWR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.